Furthermore, in a genome-wide ChIP-seq analysis of EZH2-mediated H3K27me3, high-grade glioma displayed a higher rate of H3K27me3 gene modification than low-grade glioma, and the extent of medication was similar to that of embryonic stem cells [38]. The gene discussed is EZH2; the disease is central nervous system cancer.